Generate Biomedicines

GENB

Generative AIPrecision medicineBiotech & pharmaceuticals

$14.34vs prev close▲+0.35(+2.50%)

$11.0052W Range$22.67

29% from low

-1.38 (-8.78%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.13%

1M -0.06%p

Holding ETFs

1 ETFs

ARKG

Price Effect (Buy)

Shares increased, but price decline reduced portfolio weight.

Shares +1.3% · Market value -13.8% · Weight -0.06%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.08.26	BUY	ARKG	304,851	$16.14	$4.9M
26.07.10	BUY	ARKG	54,804	$14.32	$785.1K
26.07.09	BUY	ARKG	57,462	$15.72	$903.3K
26.07.08	BUY	ARKG	61,750	$15.87	$980.0K
26.07.07	BUY	ARKG	44,170	$16.22	$716.4K
26.07.06	BUY	ARKG	92,202	$16.92	$1.6M
26.07.02	BUY	ARKG	26,483	$17.41	$461.1K
26.07.01	BUY	ARKG	69,680	$16.50	$1.1M
26.06.30	BUY	ARKG	27,949	$16.87	$471.5K
26.06.29	BUY	ARKG	136,406	$16.91	$2.3M
26.06.26	BUY	ARKG	63,768	$16.47	$1.1M
26.06.25	BUY	ARKG	31,159	$16.42	$511.6K
26.06.24	BUY	ARKG	50,900	$16.23	$826.1K
26.06.23	BUY	ARKG	404	$15.43	$6.2K
26.06.18	BUY	ARKG	15,435	$14.49	$223.7K

08.26BUY

304,851

ARKGClose$16.14Est. total$4.9M

07.10BUY

54,804

ARKGClose$14.32Est. total$785.1K

07.09BUY

57,462

ARKGClose$15.72Est. total$903.3K

07.08BUY

61,750

ARKGClose$15.87Est. total$980.0K

07.07BUY

44,170

ARKGClose$16.22Est. total$716.4K

07.06BUY

92,202

ARKGClose$16.92Est. total$1.6M

07.02BUY

26,483

ARKGClose$17.41Est. total$461.1K

07.01BUY

69,680

ARKGClose$16.50Est. total$1.1M

06.30BUY

27,949

ARKGClose$16.87Est. total$471.5K

06.29BUY

136,406

ARKGClose$16.91Est. total$2.3M

06.26BUY

63,768

ARKGClose$16.47Est. total$1.1M

06.25BUY

31,159

ARKGClose$16.42Est. total$511.6K

06.24BUY

50,900

ARKGClose$16.23Est. total$826.1K

06.23BUY

404

ARKGClose$15.43Est. total$6.2K

06.18BUY

15,435

ARKGClose$14.49Est. total$223.7K

1 / 2

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

1,630,564

Portfolio Weight

0.13%

in ETF 0.93%

Est. Value

$23M

30D Net

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Analyst Targets

avg.

$27.00

vs Current ▲ +88.3% upside

Current$14.34

Low ~ High$22.00 ~ $30.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

HC Wainwright & Co.

Buy

$30.00

+109.21%

$13.91

Maintain

2026-10-05

HC Wainwright & Co.

Buy

$30.00

+109.21%

$15.90

Maintain

2026-09-08

HC Wainwright & Co.

Buy

$30.00

+109.21%

$15.33

Maintain

2026-08-28

Morgan Stanley

Overweight

$22.00

+53.42%

$15.47

Maintain

2026-05-14

HC Wainwright & Co.

Buy

$25.00

+74.34%

$13.66

Maintain

2026-05-08

1 / 3

Avg Target

$27.00

vs Current ▲ +88.3% upside

Strong Buy

6 analysts

Strong Buy 2Buy 4

Low $22.00

Current $14.34

High $30.00

Firm	Position	Target	Upside	Close	Action	Date
HC Wainwright & Co.	Buy	$30.00	+109.21%	$13.91	Maintain	26.10.05
HC Wainwright & Co.	Buy	$30.00	+109.21%	$15.90	Maintain	26.09.08
HC Wainwright & Co.	Buy	$30.00	+109.21%	$15.33	Maintain	26.08.28
Morgan Stanley	Overweight	$22.00	+53.42%	$15.47	Maintain	26.05.14
HC Wainwright & Co.	Buy	$25.00	+74.34%	$13.66	Maintain	26.05.08

1 / 3

Price Information

Previous Close$13.99

Open$14.06

Day Range$13.94 - $14.86

52-Week Range$11.00 - $22.67

1-Year Change13.36%

Trading Volume

Volume903,103

Avg Volume (3mo)1,046,015

Valuation

Market Cap1.8B

Book Value$3.56

Shares Outstanding128,352,436

Financials

Revenue (TTM)26.5M

Net Income-268,673,984

EPS$-2.44

EBITDA-249,548,000

Profitability

P/E Ratio-

P/B Ratio4.03

Return on Equity (ROE)-

Return on Assets (ROA)-

Profit Margin0.00%

EV/EBITDA-5.79

Beta-

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)25.48

Company Overview

Generate Biomedicines utilizes machine learning and generative biology to discover and develop novel protein therapeutics. Their platform aims to create protein-based drugs, with current pipeline candidates including treatments for severe asthma and cancer. The company positions itself as an innovator in addressing complex therapeutic challenges beyond traditional methods.

P/B

4.03

High valuation

ROE

Return on Equity

Beta

Market Volatility

RSI(14)

25.5

Oversold

AI-generated summary. Not investment advice.

Generate Biomedicines

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks